Paradigm Biocapital Advisors LP Edgewise Therapeutics, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.14 Billion
- Q2 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 6,142,344 shares of EWTX stock, worth $107 Million. This represents 3.76% of its overall portfolio holdings.
Number of Shares
6,142,344
Previous 500,000
1128.47%
Holding current value
$107 Million
Previous $11 Million
632.05%
% of portfolio
3.76%
Previous 0.56%
Shares
6 transactions
Others Institutions Holding EWTX
# of Institutions
193Shares Held
118MCall Options Held
54.3KPut Options Held
70.1K-
Orbimed Advisors LLC San Diego, CA15.5MShares$270 Million7.26% of portfolio
-
Ra Capital Management, L.P. Boston, MA9.9MShares$172 Million2.84% of portfolio
-
Baker Bros. Advisors LP New York, NY7.31MShares$127 Million0.97% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$105 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X05.5MShares$95.6 Million0.04% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.1B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...